chemotherapy induced neuropathy. Other antineoplastic drugs
Conditions
Interventions
Intervention 1: in intervention group Gabapentin is prescribed 300mg orally for the first day, 300mg every 12 hour for the second day and 300mg every 8 hour for the third to fourteenth day of each ch
Treatment - Drugs
in intervention group Gabapentin is prescribed 300mg orally for the first day, 300mg every 12 hour for the second day and 300mg every 8 hour for the third to fourteenth day of each chemotherapy cycle
in control group placebo is prescribed orally one capsule for the first day, one capsule every 12 hour for the second day, one capsule every 8 hour for the third to fourteens day of chemotherapy.
Sponsors
Bakhtar Bioshimi Company
Eligibility
Sex/Gender
Female
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria : Women who have pathologically confirmed non metatstatic breast cancer; aged 18-65; candidate for receiving 4 course of paclitaxel ; good performance status (based on Karnofsky Score) Exclusion criteria : history of diabetes mellitus; previous neuropathy; chronic renal or liver disease; consumption of neurotoxic/neurotropic/neuroleptic drugs
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Taxane induced neuropathy. Timepoint: befor and after each chemotherapy session. Method of measurement: taking history and physical exam. | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective neuropathy. Timepoint: befor begining chemotherapy session and 6 week after last chemotherapy session. Method of measurement: nerve conducting study. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNima Mousavi Darzikolaee
Radiation Oncology Research Center, Cancer Institute , Imam Khomeini Hospital Complex
Outcome results
None listed